Cardiovasology

描述（由申请人提供）：在马约诊所的“血管学”博士后培训计划，在此更新，要求继续支持36至40年。通过四十年的指导职业发展，该计划已经实现了准备医生和科学家在心血管医学和生物学的独立研究职业的使命。受训人员获得了严格的科学能力，在生产力方面表现出色，在研究支持方面建立了良好的记录，并获得了学术职位，为国家多样化的劳动力做出了贡献。成就包括强有力的招聘和保留，与优秀的NIH资助的教师互动指导，强大的基础设施和合作环境，确保推出有竞争力的职业生涯。更新跨越科学-教育-实践的交叉点，以最好地装备下一代调查人员。根据最高的教育标准和尖端的技术平台，该计划是定制的，以匹配每个受训者的背景和职业道路，同时扩大兴趣和能力，以追求不断发展的科学进步。心力衰竭-重点是从实验室到床边到人群的转变-是中心主题，反映了国家发病率和死亡率趋势。该计划通过实施培训来更好地了解心力衰竭的分子和临床机制，以改善个人和公众的预防，诊断和治疗，从而启动NHLBI战略计划。利用马约诊所的主要举措，包括NIH转化科学活动中心、卫生与公众服务部东南明尼苏达州灯塔计划、NHLBI心力衰竭临床研究网络、NIH药物基因组学研究网络、NHLBI心血管细胞治疗研究网络以及明尼苏达州生物技术和医学基因组学合作伙伴关系，该计划汇集了与当地/区域/国家卓越中心互连的发现-翻译-应用连续体的协作和互补导师团队。致力于NHLBI计划的重点，更新整合了多学科培训，以实现不断变化的科学需求领域的能力。此次更新利用了学位授予计划;基于社区的心力衰竭登记和生物库;启用生物技术平台;以及推出的诊断/治疗管道。与马约诊所的个性化医学，再生医学和医疗保健提供科学的战略重点相一致，产品已经丰富，包括个性化医学和药物基因组学课程;再生医学;系统生物学和生物信息学;分子成像;遗传流行病学;比较有效性;和健康差异研究。一个研究员到教师的职业发展计划是到位，以促进教师的过渡，和少数招聘和研究计划的负责任的行为实施，以确保一致的成功。更新强调了“心血管学”计划的愿景，即在心血管研究的前沿提供最先进的培训。(End摘要）

DESCRIPTION (provided by applicant): The "Cardiovasology" Post-doctoral Training Program at Mayo Clinic, in this renewal, requests continuation of support for years 36 to 40. Through four decades of mentored career development, the Program has realized the mission of preparing physicians and scientists for independent research careers in cardiovascular medicine and biology. Trainees have acquired rigorous scientific proficiency, excelled in productivity, established track- records in research support, and secured academic placements contributing to the nation's diverse workforce. Accomplishments have included strong recruitment and retention, interactive mentoring with outstanding NIH- funded faculty, robust infrastructure and cooperative environment ensuring launch of competitive careers. The renewal spans science-education-practice intersections to best equip next generation investigators. Mapped to draw from highest educational standards and cutting-edge technological platforms, the Program is customized to match the background and career path of each trainee, while widening interests and capabilities in pursuit of evolving scientific advances. Heart failure - with focus on translation from the bench to the bedside to populations - is the central theme, reflecting national morbidity and mortality trends. The Program actuates the NHLBI Strategic Plan by implementing training for the better understanding of molecular and clinical mechanisms of heart failure aimed at improved prevention, diagnosis, and treatment of individuals and the public-at-large. Leveraging major initiatives at Mayo Clinic, including the NIH Center for Translational Science Activities, Department of Health and Human Services Southeast Minnesota Beacon Program, NHLBI Heart Failure Clinical Research Network, NIH Pharmacogenomics Research Network, NHLBI Cardiovascular Cell Therapy Research Network, and Minnesota Partnership for Biotechnology and Medical Genomics, the Program assembles collaborative and complementary teams of mentors across the discovery-translation- application continuum interconnected with local/regional/national centers of excellence. Committed to NHLBI programmatic emphases, the renewal integrates multidisciplinary training to achieve competencies in evolving areas of scientific need. The renewal capitalizes on degree-granting programs; community-based heart failure registries and biobanks; enabling biotechnology platforms; and rolled-out diagnostics/therapeutics pipelines. Aligned with Mayo Clinic Strategic Priorities of Individualized Medicine, Regenerative Medicine, and Science of Health Care Delivery, offerings have been enriched to include curricula in personalized medicine and Pharmacogenomics; regenerative medicine; systems biology and bioinformatics; molecular imaging; genetic epidemiology; comparative effectiveness; and health disparities research. A fellow-to-faculty career development program is in place to foster faculty transition, and a minority recruitment and responsible conduct of research plans are implemented to ensure consistent success. The renewal underscores the vision of the "Cardiovasology" Program to provide most advanced training at the vanguard of cardiovascular research. (End of Abstract)